CPT code 86413: COVID-19 antibody, quantitative measurement2026 Medicare lab fee · Clinical Laboratory Fee Schedule
Quantitative SARS-CoV-2 antibody testing reports measured antibody levels, distinguished from neutralizing-antibody screening or titer testing.
Medicare pays $51.43 for 86413 under the 2026 Clinical Laboratory Fee Schedule: one national amount, the same in every state and setting.
Medicare lab fee · CLFS 2026 Q4
National CLFS amount
$51.43
In effect since Jan 1, 2026. The same amount in every state, payment locality and setting.
- Geographic adjustment
- None
- Office vs facility
- Same
- Since 2024
- Unchanged
- CMS updates
- Quarterly
Medicare pays the lesser of the lab’s charge and this amount. Patients usually owe no Part B deductible or coinsurance for covered clinical lab tests.
On this page 8 sections
What 86413 covers
Code 86413 identifies a laboratory measurement of SARS-CoV-2 antibodies reported quantitatively. The result is a measured antibody level, rather than a qualitative or semiquantitative result. This code is distinct from assays specifically classified as neutralizing-antibody screening or neutralizing-antibody titer testing. Clinical laboratories perform the assay and report the result to the ordering clinician. The result does not establish active SARS-CoV-2 infection.
Report one unit for each test performed; the antibody concentration does not determine additional units. Medicare pays 86413 only through the CLFS. For 2026, the national amount is $51.43, unchanged from 2024 and 2025. The same amount applies across states and localities, with no office-versus-facility payment difference. The code is excluded from the physician fee schedule.
This summary was written with AI assistance from CMS Clinical Laboratory Fee Schedule data. Amounts on this page come directly from CMS files.
How Medicare pays 86413
Clinical lab tests aren’t priced like physician services. They’re paid from their own fee schedule, with its own rules. See the whole lab fee schedule.
One national amount
CMS sets a single Clinical Laboratory Fee Schedule amount for 86413. There’s no geographic (GPCI) adjustment, so it pays the same in every state and payment locality.
No office or facility rate
Lab tests aren’t built from relative value units, so there’s no office and facility split: the place of service doesn’t change the CLFS amount.
Updated every quarter
CMS republishes the CLFS each quarter. New tests, often proprietary laboratory analyses (PLA codes), join during the year; existing amounts are updated each January.
Excluded from the physician fee schedule
The physician fee schedule lists 86413 with status X (excluded by statute), so the test itself is paid only from the CLFS.
86413 on the lab fee schedule since 2020
86413 · CLFS 2026 Q4 (current)
$51.43
Unchanged since Apr 1, 2024
Every change on file
- Apr 1, 2024 · CLFS 2024 Q2MAC-priced → $51.43
25 quarterly CLFS releases on file, first CLFS 2020 Q4. A code missing from a quarter wasn’t on that release.
86413 compared with similar tests
- 86408COVID-19 antibodyNeutralizing antibody screen$42.13
- Choose 86413 for quantitative SARS-CoV-2 antibody measurement. Code 86408 is for neutralizing-antibody screening.
- 86409Neutralizing antibodySARS-CoV-2 titer$79.61
- Code 86409 reports a neutralizing-antibody titer; 86413 reports quantitative SARS-CoV-2 antibody measurement.
- 86328COVID-19 antibodySingle-step immunoassay$45.28
- Code 86328 describes qualitative or semiquantitative antibody testing with a single-step method; 86413 reports quantitative measurement.
- 86769COVID-19 antibodyMultiple-step method$42.13
- Code 86769 describes qualitative or semiquantitative antibody testing with a multiple-step method; 86413 reports quantitative measurement.
86413 billing questions
How does 86413 differ from SARS-CoV-2 neutralizing-antibody screening?
86413 reports quantitative SARS-CoV-2 antibody measurement. Code 86408 is for neutralizing-antibody screening.
How does 86413 differ from neutralizing-antibody titer testing?
Code 86409 is for a SARS-CoV-2 neutralizing-antibody titer; 86413 reports quantitative antibody measurement.
How many units should be reported?
Report one unit for each test performed. The measured antibody concentration does not create additional units.
Does 86413 diagnose active COVID-19 infection?
No. It measures SARS-CoV-2 antibodies and does not establish active infection.
How does Medicare pay 86413?
Medicare pays the test through the CLFS. The code is excluded from the physician fee schedule.
Where this amount comes from
FeeBase reads lab amounts directly from the CMS Clinical Laboratory Fee Schedule file for the quarter: one row per code, with its payment indicator and national amount. Contractor-priced tests are labeled, never given a made-up amount. Amounts are Medicare payment limits, not a patient’s bill or a commercial rate.
CMS CLFS 2026 Q4 · effective Oct 1, 2026 through the day before Jan 1, 2027
Show the CMS file line behind this amount
Fee sheets · Coming soon
Put 86413 and the rest of your codes on one sheet
Your codes at your locality, with payer contracts beside Medicare.
Join the waitlist